BLB&B Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

BLB&B Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-677	Closed	-$6.86K	–	281
2024 Q4	$6.86K	Hold	677	–	–	﹤0.01%	270
2024 Q3	$8.43K	Sell	677 -66	-9%	-$820	﹤0.01%	283
2024 Q2	$9.67K	Buy	+743	New	+$12.3K	﹤0.01%	276

Other funds holding KPTI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BLB&B Advisors's KPTI Position: Q1 2025 in Review

BLB&B Advisors sold out of Karyopharm Therapeutics (KPTI) in Q1 2025, closing a stake of 677 shares — an estimated $6.86K sold.

BLB&B Advisors first reported a position in KPTI in Q2 2024 and held it in 3 quarters. The position peaked at $9.67K in Q2 2024. 49 funds tracked by Wall St. Rank hold KPTI as of Q1 2025.

BLB&B Advisors reported no remaining Karyopharm Therapeutics position as of Q1 2025 after selling out during the quarter.
BLB&B Advisors sold 677 Karyopharm Therapeutics shares in Q1 2025, an estimated $6.86K.
BLB&B Advisors first reported a position in Karyopharm Therapeutics in Q2 2024 and held it in 3 quarters.
BLB&B Advisors's Karyopharm Therapeutics position peaked at $9.67K in Q2 2024.
49 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2025.

Based on BLB&B Advisors's 13F filing for Q1 2025, filed 28 Apr 2025.